Kan N, Yamasaki S, Harada T, Satoh K, Ichinose Y, Moriguchi Y, Kodama H, Ohgaki K
First Department of Surgery, Kyoto University, Faculty of Medicine, Japan.
Hum Cell. 1992 Sep;5(3):236-42.
Among several approaches to augment the therapeutic effect of adoptive immunotherapy, we focused the antitumor synergy between transferred killer cells and host's fresh lymphocytes. Immunotherapy models using murine tumors or clinical experiments revealed that preadministration of immunostimulator such as OK-432, followed by chemotherapeutic agents such as cyclophosphamide, can induce host's non-cytotoxic fresh lymphocytes that act synergistically with cultured killer cells against autologous tumor cells. Immuno-chemo-lymphocytotherapy (a sequential treatment with OK-432, chemotherapy and adoptive immunotherapy) is useful to treat the patients with advanced cancer even if the number of transferred lymphocytes is limited.
在增强过继性免疫疗法治疗效果的几种方法中，我们重点研究了转移的杀伤细胞与宿主新鲜淋巴细胞之间的抗肿瘤协同作用。使用小鼠肿瘤的免疫疗法模型或临床实验表明，预先给予免疫刺激剂（如OK-432），随后给予化疗药物（如环磷酰胺），可诱导宿主产生无细胞毒性的新鲜淋巴细胞，这些淋巴细胞与培养的杀伤细胞协同作用对抗自体肿瘤细胞。免疫化学淋巴细胞疗法（先用OK-432、化疗和过继性免疫疗法进行序贯治疗）即使在转移淋巴细胞数量有限的情况下，也有助于治疗晚期癌症患者。
